Skip to content

International Melanoma Algorithm Training Study - IMATS

An International, Multicenter, Prospective, Non-controlled, Non-randomised, Clinical Study to Collect Impedance Data of Potentially Malignant Pigmented Nevi and Histological Diagnoses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00966173
Enrollment
1800
Registered
2009-08-26
Start date
2005-12-31
Completion date
2010-07-31
Last updated
2010-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Melanoma

Brief summary

This is an international, multicenter, prospective, non controlled, non randomized, clinical study to collect electrical impedance data of potentially malignant pigmented nevi and histological diagnoses (International Melanoma Algorithm Training Study \[IMATS\]). The study objective is to collect data for training and optimization of an algorithm that can classify skin lesions using electrical impedance, i.e., to identify malignant melanomas.

Interventions

Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.

Sponsors

SciBase AB
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women of any ethnic group * Lesion located on normal healthy skin * Maximum number of eight lesions per patient * etc.

Exclusion criteria

* Lesion under finger and toe nails * Lesion located on eczema, psoriasis areas or similar * Lesion located on scars * etc.

Design outcomes

Primary

MeasureTime frame
Outcome measure not applicable. This is an algorithm training study.Q1 2010

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026